Table 3.
Bivariate and multivariable* logistic regression models for adherence (left) and discontinuation (right) to GLP-1 RA therapy at 12 and 24 months follow-up†
| Adherence | Discontinuation | |||||||||||||||
| 12 months | 24 months | 12 months | 24 months | |||||||||||||
| Bivariate | Multivariable | Bivariate | Multivariable | Bivariate | Multivariable | Bivariate | Multivariable | |||||||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| Gender | ||||||||||||||||
| Male | 0.75 | 0.51 to 1.09 | 0.77 | 0.52 to 1.14 | 0.89 | 0.62 to 1.29 | 0.89 | 0.61 to 1.31 | 1.30 | 0.92 to 1.85 | 1.20 | 0.87 to 1.78 | 1.20 | 0.82 to 1.68 | 1.10 | 0.77 to 1.61 |
| Female (reference) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Age (years) | ||||||||||||||||
| <45 | 0.93 | 0.5 to 1.7 | 0.82 | 0.43 to 1.57 | 0.7 | 0.39 to 1.28 | 0.64 | 0.34 to 1.19 | 0.80 | 0.48 to 1.46 | 0.90 | 0.52 to 1.67 | 0.70 | 0.4 to 1.26 | 0.80 | 0.42 to 1.36 |
| 45–54 | 0.93 | 0.53 to 1.64 | 0.90 | 0.5 to 1.63 | 0.86 | 0.49 to 1.51 | 0.84 | 0.47 to 1.5 | 1.20 | 0.73 to 2.04 | 1.40 | 0.8 to 2.32 | 0.90 | 0.53 to 1.55 | 1.00 | 0.57 to 1.7 |
| 55–64 | 1.36 | 0.76 to 2.46 | 1.38 | 0.75 to 2.55 | 1.33 | 0.75 to 2.38 | 1.36 | 0.75 to 2.46 | 1.10 | 0.63 to 1.79 | 1.10 | 0.63 to 1.82 | 1.00 | 0.58 to 1.75 | 1.00 | 0.58 to 1.77 |
| ≥65 (reference) | – | – | – | – | – | – | – | – | ||||||||
| Dosage | ||||||||||||||||
| Weekly | 2.92 | 1.7 to 5.02 | 3.09 | 1.78 to 5.38 | 2.19 | 1.35 to 3.56 | 2.24 | 1.37 to 3.67 | 1.60 | 1.07 to 2.49 | 1.60 | 1.07 to 2.51 | 2.10 | 1.3 to 3.36 | 2.10 | 1.28 to 3.34 |
| Daily (reference) | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Body mass index (kg/m2) | ||||||||||||||||
| (<30) | 0.40 | 0.15 to 1.04 | 0.31 | 0.11 to 0.87 | 0.74 | 0.28 to 1.93 | 0.58 | 0.21 to 1.59 | 1.60 | 0.66 to 3.87 | 1.50 | 0.58 to 3.61 | 1.70 | 0.67 to 4.41 | 1.40 | 0.54 to 3.84 |
| (30–34) | 0.81 | 0.46 to 1.45 | 0.72 | 0.39 to 1.32 | 0.76 | 0.43 to 1.34 | 0.63 | 0.35 to 1.14 | 1.80 | 1.07 to 3.15 | 1.80 | 1.05 to 3.19 | 1.50 | 0.86 to 2.61 | 1.40 | 0.79 to 2.48 |
| (35-39) | 1.18 | 0.7 to 1.99 | 1.03 | 0.6 to 1.77 | 1.14 | 0.68 to 1.89 | 0.97 | 0.58 to 1.65 | 1.50 | 0.91 to 2.37 | 1.40 | 0.87 to 2.33 | 1.30 | 0.82 to 2.17 | 1.20 | 0.75 to 2.01 |
| (40-44) | 1.04 | 0.63 to 1.71 | 0.96 | 0.57 to 1.61 | 1.00 | 0.61 to 1.63 | 0.92 | 0.55 to 1.51 | 1.60 | 0.99 to 2.53 | 1.50 | 0.95 to 2.45 | 1.50 | 0.91 to 2.33 | 1.40 | 0.84 to 2.22 |
| (≥45) (reference) | – | – | – | – | – | – | – | – | ||||||||
Bold values are statistically significant.
*Model adjusted for gender, age, dosage, and BMI.
†Adherence assessed among patients with two or more GLP-1 RA prescriptions.
BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist.